More to come

Discussion in 'Purdue' started by anonymous, Feb 9, 2018 at 11:03 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Purdue will dissolve the sales force in June after the contract is completed with Symproic. They only kept what little sales force they have left to fulfill their number commitment. There will be no products to promote after June.

    Purdue already has this in a written plan. I pray that each of you left here will get out while you can. Stop listening to their empty promises or you’ll be next.
     

  2. anonymous

    anonymous Guest

    Truth. 235 was what they agreed to in the Shionogi contract- and layoffs put them at that headcount. If anyone fails to plan ahead and protect themselves and their families, that’s on you.

    My concern for those kept (even if you mock the current severance) is that they are so broke from payouts for the poop drug and lawsuits that you walk away with less than we did.

    No one is safe there. It’s militant, if that is how you choose to live, that’s on you. However, life is too short to be under the control of the likes of Marv
     
  3. anonymous

    anonymous Guest

    False. The contract expires in October 2020.
     
  4. anonymous

    anonymous Guest


    LMAO! Here come all the damn lies again! This place is sick! Good luck bro on that job search come June.
     
  5. anonymous

    anonymous Guest

    No co-promote contract signs for a concrete 3 Years, idiot.
    They have a review period (usually 9-11 months out) and determine if they want to extend for another year based on sales results. At the rate of where numbers are, I’d be shocked if they just don’t buy out the contract early (before the 9-11 months). Purdue is only 11.6% to goal since launch. With the rate of the declining opioid market Movantic is also taking a nose dive in sales quarter over quarter, in fact, they have taken a 24% decline for qt 4. And before you say, “it’s because S came to market”, S only has 3% of the PAMORA market. Based off the indication (opioid patients) S will continue to struggle fiercely in this highly scrutinized market.
     
  6. anonymous

    anonymous Guest

    Poster doesn’t understand contract it’s basically a trial run every eleven months and can easily be broken. Numbers are being withheld and many will be gone by June and won’t understand why
     
  7. anonymous

    anonymous Guest

    Are you saying that management is going to "encourage" reps to leave PP by issuing PIPs and applying more scrutiny to the sales force?
     
  8. anonymous

    anonymous Guest

    Yes, the contract ends in October 2020. And apparently PP will have pay more of the promotional costs associated with the contract this June of 2018.

    All of you should be smart enough to realize that PP could easily pay any penalty to Shionigi to get out of the contract early. And what will the 235 Surviving reps sell then???

    There might be ANOTHER layoff in the next few months. Just saying......
     
  9. anonymous

    anonymous Guest


    Correct. The penalty was too great to dissolve the whole sales force before the review month of June. So they stuck with what they had to per contract guidelines 235 reps just to make it to that period (June) at which point they will walk away and pay their penalty for ending early. I was retained but will be out by the end of the month.
     
  10. anonymous

    anonymous Guest

    Some very intelligent posters here dint fit in with this company for sure
     
  11. anonymous

    anonymous Guest

    I wonder how hard the home office gets hit this week.
     
  12. anonymous

    anonymous Guest

    Move on and don’t be bitter! There is a life after Purdue. The Business Development group has failed the company miserably over the past 20 years, but they are still there. They never diversified the portfolio through R&D or meaningful acquisitions. Riding the opioid cash cow was their undoing. It is still a good business! They made 1.7 billion on OxyContin last year! Why innovate or grow when you can off the machine.

    Fire the people in the business development and rebuild the company. These people are directly responsible for the business failure of the company. Hold them accountable for a change!
     
  13. anonymous

    anonymous Guest

    It won't be pretty. There will be a skeleton crew left to help coordinate the final shutdown and a few execs floating around in a daze. At least they won't have to deal with shipping all of this garbage back to HQ though!
     
  14. anonymous

    anonymous Guest

    When do you think The Final Shutdown will occur? Some people on Cafepharma are predicting that the next big round of layoffs will be in the June 2018 time frame.
     
  15. anonymous

    anonymous Guest

    PURDUE CANNOT COMPETE! This company is WASHED UP! If you make the decision to stay to "see what happens" - let me write the ending. Sacklers make money, you will NEVER get a good product to sell, you will live in fear of layoffs for next 3 years.
    The industry has passed by Purdue and Purdue is now a bottom of the barrel company. A decision to remain here is a foolish one.
     
  16. anonymous

    anonymous Guest

    the Bus Dev group, what a joke, along with Marketing!! Remember MI, he is the "blind squirrel" of pharma. he launched oxy, had zero idea what he had. THink of ALL the successes after. Marketing launched 11 products and had exactly zero successful product launches after oxy
     
  17. anonymous

    anonymous Guest

    What happened to these individuals? Absolutely nothing! They are still there, even now!
     
  18. anonymous

    anonymous Guest

    Mark Timney AKA Mr Transformative Deal used to say that the Business Development people were looking for the "right deal, at the right time and at the right price".

    How many great business development deals did these stellar people produce?

    Thought so.....
     
  19. anonymous

    anonymous Guest

     
  20. anonymous

    anonymous Guest

    Well this poster is a regular Nostradamus. Must've been Marv or Craig that made the OP. Bravo.